Fortune Business Insights predicts the Global Intravenous Immunoglobulin Market to reach a value of US$ 15,789.1 Mn from US$ 9,787.6 Mn. The forecast period is set from 2018 and the market is expected to grow at a CAGR of 6.2%. All information related to the market is provided in the report, titled, “Intravenous Immunoglobulin Market Size, Share and Global Trend by Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), Form (Liquid, Lyophilized), End User (Hospitals, Clinics, Homecare) & Geography Forecast till 2025”. The rising incidence of immunodeficiency diseases in both emerging and developed nations is propelling growth of the Intravenous Immunoglobulin market.
Increasing Adoption of Immunoglobulins to Help Asia Pacific Register Fastest Growth
According to the report, The Global Intravenous Immunoglobulin Market was dominated by North America with a market value of US$ 5,587.4 Mn in 2017. The region is likley to remain dominant through the forecast period as well due to the presence of first line treatment for critical immune disorders. Other factors boosting the market in the region are rising number of patients and efficient results of the intravenous immunoglobulin treatment.
On the other side, the market in Asia Pacific is anticipated to grpow at faster rate in the coming years on account of the rise in awareness about the treatment option avaiulable for immunologic deficiencies. In addition to this, the rise in adoption and expenditure of immunoglobulins in economies such as Japan, China,and Indiais anticipated to boost the market in the region.
- Primary Immunodeficiency
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Guillain-Barré Syndrome (GBS)
- Immune Thrombocytopenic Purpura (ITP)
- Multifocal Motor Neuropathy (MMN)
By End User
- North America (the U.S., and Canada)
- Europe (Germany, U.K., France, Italy, Spain, Scandinavia, and Rest of Europe)
- Asia Pacific (China, India, Japan, Australia, South East Asia, and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, and Rest of Latin America
- Middle East & Africa (GCC, South Africa, and Rest of Middle East & Africa)
Top Key Players Covered:
Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the global Intravenous Immunoglobulin market. Some of the companies operating the global Intravenous Immunoglobulin market are;
- CSL Behring
- Grifols, S.A.
- Kedrion S.p.A
- Bio Products Laboratory Ltd.
- Biotest AG
- China Biologic Products Holdings, Inc.
- LFB SA and Shanghai RAAS Blood Products Co., Ltd.
Grifols, S.A., Leading Market with Better Product Offerings
Analysts at Fortune Business Insights foresees the Grifols, S.A., to emerge as the dominant player in the global market for intravenous immunoglobulin market. This is because this company was leading the market in the year 2017 as well, all because oftheir product offerings and the usual route of administration, whioch ultimately dominated a considerate proportion of share ion the market. Besides this, Grifols, S.A., accounts for largest revenues from well developed regions namely Europe and North America.
More Trending Topics From Fortune Business [email protected]